Compare MKTW & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MKTW | MREO |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9M | 50.3M |
| IPO Year | 2020 | 2017 |
| Metric | MKTW | MREO |
|---|---|---|
| Price | $20.50 | $0.28 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | ★ $23.76 | $1.96 |
| AVG Volume (30 Days) | 15.3K | ★ 655.7K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | ★ 8.50% | N/A |
| EPS Growth | ★ 1183.33 | 16.67 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $512,403,000.00 | $500,000.00 |
| Revenue This Year | N/A | $59.51 |
| Revenue Next Year | $9.24 | $2,326.81 |
| P/E Ratio | $170.01 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $13.49 | $0.20 |
| 52 Week High | $23.00 | $2.37 |
| Indicator | MKTW | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 40.40 |
| Support Level | $19.19 | $0.27 |
| Resistance Level | $21.05 | $0.35 |
| Average True Range (ATR) | 0.84 | 0.02 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 24.87 | 20.70 |
Marketwise Inc is a multi-brand subscription services platform providing premium financial research, software, education, and tools for investors. Its products are built for high-value financial research, education, actionable investment ideas, and investment software. It is a digital, direct-to-consumer company offering its research across a variety of platforms, including mobile, desktop, and tablets.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).